10/18
11:53 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $50.00 price target on the stock.
Low
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $50.00 price target on the stock.
10/18
11:21 am
otlk
Rating for OTLK
Medium
Report
Rating for OTLK
9/3
06:15 am
otlk
Rating for OTLK
Medium
Report
Rating for OTLK